Lumakras (sotorasib) vs Rybrevant (amivantamab-vmjw)
Lumakras (sotorasib) vs Rybrevant (amivantamab-vmjw)
Lumakras (sotorasib) is a targeted therapy specifically designed for non-small cell lung cancer (NSCLC) patients with a KRAS G12C mutation, functioning as an inhibitor that directly targets the mutant KRAS protein. Rybrevant (amivantamab-vmjw), on the other hand, is a bispecific antibody that targets both EGFR and MET receptor pathways and is used for treating NSCLC with EGFR exon 20 insertion mutations. When deciding between these two medications, it is crucial for a patient to undergo genetic testing to determine the presence of either the KRAS G12C mutation or EGFR exon 20 insertion mutations, as this will directly influence which medication is appropriate for their specific cancer profile.
Difference between Lumakras and Rybrevant
| Metric | Lumakras (sotorasib) | Rybrevant (amivantamab-vmjw) |
|---|---|---|
| Generic name | Sotorasib | Amivantamab-vmjw |
| Indications | For the treatment of adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. | For the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, after failure of platinum-based therapy. |
| Mechanism of action | Targets the KRAS G12C mutation and inhibits the KRAS GTPase. | Bispecific antibody that targets EGFR and MET receptors. |
| Brand names | Lumakras | Rybrevant |
| Administrative route | Oral | Intravenous |
| Side effects | Diarrhea, musculoskeletal pain, nausea, fatigue, liver damage, cough, and dyspnea. | Infusion-related reactions, skin rash, paronychia, musculoskeletal pain, nausea, fatigue, edema, stomatitis, and dyspnea. |
| Contraindications | Hypersensitivity to sotorasib or any of the excipients. | Hypersensitivity to amivantamab-vmjw or any of its excipients. |
| Drug class | KRAS G12C inhibitor | Bispecific EGFR and MET antibody |
| Manufacturer | Amgen Inc. | Janssen Biotech, Inc. |
Efficacy
Lumakras (sotorasib) Efficacy in Lung Cancer
Lumakras (sotorasib) is a medication specifically designed for the treatment of non-small cell lung cancer (NSCLC) with a particular genetic mutation known as KRAS G12C. This mutation occurs in a small subset of patients with NSCLC and is known for being particularly difficult to treat. The efficacy of Lumakras was evaluated in a phase 2 clinical trial, which demonstrated that sotorasib provided a significant benefit in terms of tumor shrinkage and disease control. Patients treated with Lumakras showed a response rate, which is a reduction in tumor size, indicating that the drug can effectively target and reduce cancerous growth in the lungs.
The clinical trial results also revealed that Lumakras could lead to a median progression-free survival (PFS) time, which is the length of time during and after medication that a patient lives with the disease without it getting worse. This suggests that Lumakras can delay the progression of NSCLC in patients with the KRAS G12C mutation. The treatment was generally well-tolerated, with manageable side effects, further supporting its efficacy in this patient population.
Rybrevant (amivantamab-vmjw) Efficacy in Lung Cancer
Rybrevant (amivantamab-vmjw) is another targeted therapy approved for the treatment of NSCLC, specifically for patients with tumors that have epidermal growth factor receptor (EGFR) exon 20 insertion mutations. These mutations are associated with a poor prognosis and resistance to conventional EGFR tyrosine kinase inhibitors. The efficacy of Rybrevant was demonstrated in a multicenter, open-label, phase 1 clinical trial, where it showed a notable response rate in patients who had received prior platinum-based chemotherapy.
Patients treated with Rybrevant experienced a reduction in tumor size, and the medication also showed a median duration of response, indicating that the effects of the treatment are sustained over a period. Moreover, Rybrevant has been associated with a median overall survival, which is a key indicator of its efficacy in extending the lives of patients with this specific type of lung cancer. The drug's approval provides a new treatment option for patients with EGFR exon 20 insertion mutations, who previously had limited targeted therapies available.
Regulatory Agency Approvals
Lumakras
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Medicines & Healthcare products Regulatory Agency (MHRA), United Kingdom
Rybrevant
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Lumakras or Rybrevant today
If Lumakras or Rybrevant are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us